


ORIGINAL ARTICLE

Ovarian markers and irregular menses among women with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications study

C. Kim¹  | R.S. Miller² | B.H. Braffett³ | Y. Pan³ | V.L. Arends⁴ | A.K. Saenger⁴ | A. Barnie⁵ | A.V. Sarma⁶ | for the EDIC Research Group

¹Departments of Medicine, Obstetrics & Gynecology, and Epidemiology, University of Michigan, Ann Arbor, MI, USA

²Department of Pediatrics, University of Maryland, Baltimore, MD, USA

³The Biostatistics Center, George Washington University, Rockville, MD, USA

⁴Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA

⁵Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada

⁶Department of Urology, University of Michigan, Ann Arbor, MI, USA

Correspondence

Catherine Kim, Departments of Medicine, Obstetrics & Gynecology, and Epidemiology, University of Michigan, Ann Arbor, MI, USA. Email: cathkim@umich.edu

Funding information

National Institutes of Health, Grant/Award Number: U01 DK094176, U01 DK094157 and DK098129

Summary

Objective: Women with type 1 diabetes have increased risk of infertility compared to women without diabetes even after adjustment for irregular menses, but aetiologies are incompletely understood. Our aim was to examine the prevalence of abnormalities in ovarian markers consistent with polycystic ovary syndrome in women with type 1 diabetes and associations with irregular menses and diabetes-specific variables.

Design, Patients and Measurements: We conducted a secondary analysis of women in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC), a randomized trial and observational follow-up of intensive insulin therapy for type 1 diabetes. We included women with anti-Müllerian hormone (AMH) measurements among women not using oral contraceptives ($n = 187$). Initial AMH and testosterone measures were performed between EDIC years 1 and 4. History of irregular menses was assessed annually.

Results: The median age of women was 35 (interquartile ratio 29, 40) years; 133 (35%) had elevated AMH and 62 (17%) reported irregular menses. Twelve per cent of women had relative elevations in total testosterone. In multivariable models, lower insulin dosages were associated with higher AMH concentrations ($P = .0027$), but not diabetes duration, glycemic control, body mass index or irregular menses. Neither irregular menses nor diabetes-specific variables were associated with testosterone concentrations.

Conclusions: Among women with type 1 diabetes in their thirties, abnormalities in ovarian markers are common and not associated with irregular menses and thus may partially account for decreased fecundity in women with type 1 diabetes.

KEYWORDS

fertility, ovary, type 1 diabetes, women

1 | INTRODUCTION

Women with type 1 diabetes have a higher risk of infertility compared to women without diabetes, even after accounting for the higher prevalence of irregular menses among women with type 1 diabetes.^{1–4} This

higher risk has been attributed to suboptimal glycemic control^{4,5} as well as the higher prevalence of autoimmune diseases such as thyroid disorders among women with type 1 diabetes.⁶ Women with type 1 diabetes may also have a high prevalence of polycystic ovary syndrome (PCOS), suggested by elevated levels of ovarian markers such

as anti-Müllerian hormone (AMH)⁷ and testosterone which are made by the gonads.⁸

Few studies have examined these ovarian markers among women with type 1 diabetes after their adolescence and early twenties. For several reasons, it is important to examine ovarian markers and predictors of such markers at older ages. In general, women are at increased risk of infertility as they age, particularly in their thirties or their 4th decade of life.⁹ Due to years of intensive insulin therapy, women with type 1 diabetes may be particularly vulnerable to obesity as they age.¹⁰ Longer duration of diabetes and prolonged exposure to elevations in glucose could also adversely affect the ovary through deposition of advanced glycation end-products.¹¹ Exogenous insulin may also have gonadotropic effects,¹² particularly because supraphysiologic systemic insulin levels are significantly higher in persons with type 1 diabetes due to the need to achieve physiologic levels in the portal circulation.¹³

Therefore, due to previous reports noting increased risk for infertility among women with type 1 diabetes as well as prior reports noting high prevalence of PCOS among women with type 1 diabetes,¹³ we examined the prevalence of elevations in AMH and testosterone and associations with irregular menses and diabetes-specific variables. We conducted a secondary analysis of a large population of well-characterized reproductive-age women ($n = 379$ women) with type 1 diabetes with an average of 35 years. We used data from participants in Epidemiology of Diabetes Interventions and Complications (EDIC) study,¹⁴ which is the ongoing observational follow-up to the Diabetes Control and Complications Trial (DCCT).¹⁵ We hypothesized that irregular menses as well as longer diabetes duration, higher body mass index (BMI), poorer glycemic control and higher insulin dosage would be associated with abnormal concentrations in ovarian markers.

2 | MATERIALS AND METHODS

2.1 | Population and Setting

The DCCT and EDIC studies have been described in detail. Briefly, the DCCT was a multicenter, randomized clinical trial designed to compare the impact of intensive vs conventional diabetes treatment on the development and progression of early microvascular complications of type 1 diabetes.¹⁶ From 1983 to 1989, 1441 patients (including 680 women) were enrolled at 29 centres. The goal of intensive therapy was to maintain glycemic control as close to the nondiabetic range as possible using ≥ 3 daily insulin injections or an insulin pump, with dose adjustment guided by frequent self-monitoring of blood glucose. Conventional treatment consisted of 1-2 daily insulin injections without stipulated target glucose concentrations. The DCCT included a primary prevention cohort and a secondary intervention cohort. The primary prevention cohort consisted of 726 subjects with no retinopathy, urinary albumin excretion rate < 40 mg/24 h and diabetes duration of 1-5 years at DCCT baseline. The secondary intervention cohort consisted of 715 subjects who had nonproliferative retinopathy, urinary albumin excretion rate ≤ 200 mg/24 h and diabetes duration of 1-15 years. Individuals were excluded from participating in the DCCT if they

were hypertensive, taking any blood pressure or lipid-lowering medications, or had a history of symptomatic ischaemic heart disease or symptomatic peripheral neuropathy. Informed consent was obtained from all participants through the institutional review boards at participating centres.

Beginning in 1994 and continuing to the present, clinical, behavioural and biochemical end-points have been obtained annually during EDIC by history, physical examination and laboratory testing. Variables include smoking, BMI, waist circumference, insulin dosage, medication use and haemoglobin A1c (HbA1c). The EDIC standardized annual history included a detailed interview regarding menstrual patterns or discontinuation of menses, gynaecologic surgeries, and use of exogenous hormones, particularly oral contraceptive pill (OCP) use.¹⁷ At each of these annual interviews, women were asked "Since the last visit, has the patient had any changes to the conditions mentioned below?" "Irregular menses" was specifically listed as a condition, and women were classified as having any history of irregular menses (yes/no).

Under a separate ancillary study mechanism, a sample of 415 women who had not undergone gynaecologic surgery was selected for measurement of AMH. Strategies for sample selection have been previously described¹⁸ (Figure S1). Women underwent premenopausal AMH measurement as close to possible at EDIC baseline and another AMH measurement at EDIC year 10 or prior to menopause; a subgroup of 50 women underwent up to 4 measures prior to menopause. For the purposes of this report, we examined the subset of women not using OCPS who had an AMH measurement and a testosterone measurement obtained during EDIC years 1-4, when women were on average 36-38 years old.

Measurement of AMH concentrations was conducted by the EDIC Central Biochemistry Laboratory at the University of Minnesota (Minneapolis, MN) using a modified second-generation enzyme-linked immunosorbent assay from Beckman Coulter (Webster, TX). The limit of quantification and limit of detection for the Gen II AMH assay are 1.14 pmol/L and 0.571 pmol/L, respectively. The modified Gen II assay includes a predilution step which avoids interference with active complement binding.¹⁸ In the EDIC laboratory, the coefficients of variation were 8.1% at a mean concentration of 23.46 pmol/L and 4.2% at a mean concentration of 59.26 pmol/L. For values less than the limit of quantification but above the lower limit of detection, SoftMax Pro software (Sunnyvale, CA) was used to plot values, fit a cubic regression curve and create splines which were then used to calculate AMH concentrations.

Total serum testosterone was quantitated at the EDIC CBL using a rapid liquid chromatography-tandem mass spectrophotometry assay with a limit of detection of 0.0817 nmol/L. The assay was certified by the Centers for Disease Control Hormone Standardization Program (<http://www.cdc.gov/labstandards/hs.html>). Interassay coefficients of variation were 3.0% at 6.576 nmol/L and 2.6% at 28.53 nmol/L.

2.2 | Statistical analysis

We examined the proportion of women with elevated AMH, elevated testosterone concentrations and histories of irregular menses, as well as combinations of these reproductive abnormalities. Table 1 shows

the women's baseline characteristics. There are currently no guidelines or recommendations regarding absolute cutpoints for elevations in AMH⁷ or testosterone,¹⁹ only that the testosterone cutpoint should reflect the upper 2.5-5th percentile of the distribution for women in the specific study population, which by definition precludes estimates of prevalence. Therefore, we used values identified as consistent with polycystic ovary morphology (PCOM) obtained from another study of women with type 1 diabetes which used the same AMH assay as our study. In the study by Lebkowska et al²⁰ an AMH concentration of 26.70 pmol/L had the greatest area under the curve for PCOM (0.85, 95% CI 0.73, 0.97) with 90.2% sensitivity and 70.3% specificity compared to transvaginal ultrasound. In that study, elevations in testosterone concentrations were defined as 3.05 nmol/L, with an interquartile range of 1.74-3.82 nmol/L.²⁰ Therefore, in our analysis, we examined the proportion of women who exceeded 1.74 nmol/L and 3.05 nmol/L of total testosterone.

TABLE 1 Participant characteristics at EDIC baseline among women with anti-Müllerian hormone (AMH) and testosterone measurements. Means \pm standard deviations or N (%) shown

	Women with AMH and testosterone measures (n = 187)
Age (years)	35.4 \pm 6.9
Duration of diabetes (years)	14.4 \pm 5.2
Baseline oral contraceptive use (n, %)	5 (2.8) ^a
Current smoking (n, %)	29 (16.0)
Irregular menses (n, %)	37 (20.8)
Body mass index (kg/m ²)	26.5 \pm 4.2
Waist circumference (cm)	80.1 \pm 9.3
Time-weighted insulin dose (units/kg/day)	0.67 \pm 0.18
Time-weighted HbA1c (%)	8.1 \pm 1.3
AMH (pmol/L)	28.7 \pm 32.1
AMH \geq 26.7 pmol/L (n, %)	68 (36.4)
AMH \geq 26.7 pmol/L AND irregular menses (n, %)	17 (9.1)
Testosterone (nmol/L)	1.20 \pm 1.02
Testosterone \geq 1.74 nmol/L (n, %)	23 (12.2)
Testosterone \geq 1.74 nmol/L AND irregular menses (n, %)	8 (4.3)
Testosterone \geq 1.74 nmol/L AND AMH \geq 26.7 pmol/L (n, %)	19 (10.1)
Testosterone \geq 1.74 nmol/L AND AMH \geq 26.7 pmol/L AND irregular menses (n, %)	7 (3.7)
Testosterone \geq 1.74 nmol/L AND AMH \geq 26.7 pmol/L AND irregular menses (n, %)	10 (5.3)
Women with at least 2 of the following: AMH \geq 26.7 pmol/L /, testosterone \geq 1.74 nmol/L or irregular menses (n, %)	30 (16.0)

^aWomen using OCPs at the time of AMH and testosterone measurement were excluded, although 5 women were using OCPs at baseline but not at subsequent visits when testosterone was measured.

We examined the unadjusted associations between the initial AMH/testosterone concentrations in EDIC years 1-4 and other variables measured concurrently (Table 2). Multivariable models were used to examine the adjusted associations between risk factors and AMH or testosterone (Tables S1 and S2). AMH and testosterone concentrations were log-transformed for analysis. The per cent change in AMH or testosterone concentration per unit increase in concurrent risk factor or the per cent difference in the mean AMH concentration is presented. HbA1c levels and total daily insulin dose were evaluated as time-weighted variables defined as the running arithmetic mean up to the point of the dependent variable measurement. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).

3 | RESULTS

Table 1 presents the participant characteristics at EDIC baseline. Women had a median age of 35 years (interquartile range 29-40 years). The average diabetes duration was 14 years. Approximately 1 in 5 women reported current cigarette use. The average BMI was consistent with overweight. Approximately 21% of women reported a history of irregular menses and over one-third had elevated AMH concentrations defined as \geq 26.70 pmol/L. Twenty-three (12.2%) had testosterone concentrations \geq 1.74 nmol/L, and 5 (2.7%) had concentrations \geq 3.05 nmol/L. Sixteen per cent of women had at least 2 reproductive abnormalities, and only 7 women had irregular menses, elevations in AMH and elevations in testosterone.

Figure 1 shows AMH by age, and Figure 2 shows testosterone concentrations by age. Table 2 presents the mean initial AMH and testosterone concentrations in EDIC years 1-4 by tertiles of each concurrent risk factor. In these unadjusted comparisons, younger age, higher testosterone and irregular menses were associated with higher AMH concentrations. Higher tertiles of AMH were associated with higher testosterone concentrations. AMH and testosterone concentrations were not significantly associated with tertiles of BMI, waist circumference, insulin dosage or glycemic control.

Tables S1 and S2 present risk factor associations with AMH and testosterone concentrations in multivariable linear regression models. Factors associated with higher AMH concentrations included younger age, not smoking, lower insulin dosages and higher testosterone concentrations. Significant risk factors for testosterone included current smoking and higher AMH concentrations. Neither AMH nor testosterone concentrations were associated with irregular menses in multivariable models. In multivariable logistic regression models, the only variable associated with the presence of at least 2 reproductive abnormalities was age, with older age correlating with a lower odds (odds ratio [OR] 0.87, 95% CI 0.80, 0.94).

4 | DISCUSSION

As women age, they are more likely to report difficulties with fertility, with fecundity decreasing gradually after 32 years of age and

TABLE 2 Mean \pm SD initial anti-Müllerian hormone (AMH) and testosterone concentrations in EDIC years 1-4 by concurrent risk factors. P-values in bold type indicate $P < .05$

Risk factor	AMH			Testosterone		
	N = 187	(pmol/L)	P-value	N = 187	(nmol/L)	P-value
Age (years)						
20-29 years	37	47.9 \pm 35.9	<.0001	37	1.46 \pm 0.92	.17
30-39 years	99	29.6 \pm 31.5		99	1.19 \pm 1.18	
40-50 years	51	12.9 \pm 20.9		51	1.04 \pm 0.67	
Duration of diabetes (years)						
Tertile 1 (6-11)	50	26.8 \pm 27.6	.59	50	1.32 \pm 1.57	.61
Tertile 2 (11-17)	64	32.1 \pm 33.9		64	1.16 \pm 0.81	
Tertile 3 (17-26)	73	27.1 \pm 33.5		73	1.15 \pm 0.63	
Oral contraceptive use						
Yes	-	-	-	-	-	-
No	187	28.7 \pm 32.1		187	1.20 \pm 1.02	
Current smoking						
Yes	28	19.9 \pm 27.4	.12	28	1.27 \pm 0.62	.68
No	159	30.2 \pm 32.7		159	1.19 \pm 1.07	
History of irregular menses						
Yes	49	40.1 \pm 44.5	.004	49	1.26 \pm 0.82	.62
No	136	25.0 \pm 25.4		136	1.18 \pm 1.08	
Body mass index (kg/m ²)						
Tertile 1 (18.9-23.7)	49	31.4 \pm 31.85	.79	49	1.00 \pm 0.43	.26
Tertile 2 (23.7-26.7)	62	27.5 \pm 34.0		62	1.27 \pm 1.41	
Tertile 3 (26.7-42.1)	76	27.9 \pm 31.1		76	1.28 \pm 0.89	
Waist circumference (cm)						
Tertile 1 (59.8-73.7)	46	20.7 \pm 26.0	.14	46	0.97 \pm 0.44	.08
Tertile 2 (73.8-81.0)	62	32.5 \pm 34.2		62	1.14 \pm 0.49	
Tertile 3 (81.1-117.2)	79	30.4 \pm 33.2		79	1.38 \pm 1.45	
Time-weighted insulin dose (units/kg/day)						
Tertile 1 (0.20-0.58)	61	30.7 \pm 38.3	.76	61	1.23 \pm 1.46	.95
Tertile 2 (0.58-0.74)	64	26.5 \pm 29.3		64	1.17 \pm 0.74	
Tertile 3 (0.74-1.39)	62	29.1 \pm 28.5		62	1.21 \pm 0.71	
Time-weighted haemoglobin A1c (%)						
Tertile 1 (5.6-7.3)	56	27.8 \pm 31.0	.62	56	1.19 \pm 0.85	.89
Tertile 2 (7.4-8.4)	65	26.4 \pm 29.4		65	1.16 \pm 0.58	
Tertile 3 (8.5-12.2)	66	31.7 \pm 35.7		66	1.25 \pm 1.42	
AMH (ng/mL)						
Tertile 1 (0.04-1.4)			-	60	0.90 \pm 0.57	<.0001
Tertile 2 (1.5-3.8)				63	1.05 \pm 0.62	
Tertile 3 (3.9-23.5)				64	1.63 \pm 1.44	
Testosterone (ng/dL)						
Tertile 1 (2.8-23.5)	61	16.1 \pm 20.5	<.0001			-
Tertile 2 (23.5-33.6)	59	22.3 \pm 21.1				
Tertile 3 (33.6-329.7)	67	45.8 \pm 40.6				

more rapidly after 37 years of age.⁹ Few reports have examined abnormalities in ovarian markers in women with type 1 diabetes in this age range, although as many as a third of younger women with

type 1 diabetes may have PCOM and androgen abnormalities.¹³ In a relatively large cohort of well-phenotyped women with type 1 diabetes with a median age of 35 years, we found that AMH elevations




FIGURE 1 Scatterplot of age (years) vs anti-Müllerian hormone (AMH) concentrations (pmol/L) [Colour figure can be viewed at wileyonlinelibrary.com]




FIGURE 2 Scatterplot of age (years) vs total testosterone concentrations (nmol/L) [Colour figure can be viewed at wileyonlinelibrary.com]

affected over one-third of the population, consistent with the presence of PCOM. Elevations in testosterone were considerably less common. Although almost 1 in 5 women reported irregular menses, irregular menses were not correlated with ovarian markers. Therefore, elevations in AMH are common and could potentially explain decreased fecundity in women with type 1 diabetes, apart from irregular menses.

We also found that factors associated with higher AMH included younger age, higher testosterone concentrations and not currently smoking as has been reported in other studies.²¹ In contrast to other reports, we note that lower insulin doses over time were also correlated with higher AMH concentrations, suggesting that in this late reproductive-age population, higher exogenous insulin does not act as

a gonadotropin and thus does not result in elevations in ovarian markers. Previous reports conflict.^{20,22} We may have found different results due to the relatively older age of our population and our use of time-weighted variables, which accounts for longitudinal changes in insulin dosing over time, as opposed to previous cross-sectional analyses. We also included a significantly larger number of women than in previous reports, which included less than women with type 1 diabetes.^{20,22}

The factors associated with higher testosterone concentration included higher AMH and a history of smoking, which was likely due to the fact that women using OCPs were excluded; thus, women who had testosterone measurement were younger and already more likely to smoke than women who did not have testosterone measurement. Due to the presence of insulin receptors on the ovary and associations

between elevations in testosterone with PCOM, others have hypothesized that exogenous insulin may act as a gonadotropin in type 1 diabetes. In EDIC women, insulin did not appear to be associated with elevated testosterone concentrations.²³ This may be because the presence of significant elevations in testosterone was rare in EDIC women. In addition, previous reports note that among women with known hyperandrogenemia, androgen levels decline as women age particularly beginning in the 4th decade of life,^{24,25} which may also account for the lower androgen levels.

Neither AMH nor testosterone elevations were correlated with the prevalence of irregular menses, even though histories of irregular menses were common in the EDIC population and among other cohorts of women with type 1 diabetes.^{26,27} Thus, irregular menses may independently contribute to decreased risk of fecundity apart from these pathways. Multiple endocrinologic disorders can result in irregular menses, including disorders that are more common in women with type 1 diabetes than in women without diabetes; we have previously reported that the risk of hypothyroidism was high in EDIC, with approximately 25% of women noting hypothyroidism by the 18th year of EDIC follow-up.⁶ Others have noted that women with type 1 diabetes have abnormal gonadotropin-releasing hormone pulse generation which may also result in irregular menstrual cycles.²⁸

Strengths of this report include its large and well-characterized population of women with type 1 diabetes who were of older age than in previous reports examining ovarian markers. We used an AMH assay with higher sensitivity and precision than presented in previous studies that used first-generation assays, which may be less subject to issues of performance and interpretation than transvaginal ultrasound.⁷ Testosterone was performed with mass spectrometry, generally considered more sensitive than other methods,²⁹ an issue particularly important in women. This report also has several limitations. The assessment of reproductive abnormalities was not a primary objective of the EDIC study, and thus, women were not asked to record cycle length with menstrual diaries. EDIC did not conduct transvaginal ultrasounds to assess ovarian morphology nor clinical assessments of hyperandrogenism such as measurement of Ferriman-Gallwey scores. Difficulties with fertility and actual thyroid hormone levels were not assessed. There are no universal cutpoints for abnormal levels of AMH and testosterone.¹⁹ We examined cutpoints corresponding with the 25th percentile of total testosterone as well as with the 50th percentile compared to previous reports in younger populations, and thus, it is unlikely that lower cutpoints would lead to a significantly higher prevalence of hyperandrogenism.²⁰ Testosterone was assessed only in women not using OCPs, and it is possible that clinical hyperandrogenemia was masked among the 14% of women who were OCP users or that testosterone concentrations were less elevated among women who chose not to use OCPs, thus underestimating the proportion of women with hyperandrogenemia.

Finally, it is unknown whether the relationships between AMH, testosterone, irregular menses and PCOS differ between women with and without type 1 diabetes. We did not conduct a comparison between women with and without diabetes. In a previous report,

we noted that women in EDIC had lower AMH concentrations than women in a control group and that these lower concentrations were primarily attributable to a slightly lower prevalence of elevated AMH concentrations.¹⁸ Aside from the comparison of women in EDIC with a control group, 2 previous reports have noted that women with type 1 diabetes had slightly lower AMH concentrations than women without type 1 diabetes.^{20,30} Reports have conflicted as to whether testosterone concentrations differ between women with and without type 1 diabetes. Lebkowska et al. noted that testosterone levels were similar among 37 women with type 1 diabetes vs 42 women without diabetes by PCOS status,²⁰ and Soto et al.³¹ and Codner et al.²² found that testosterone levels were similar in 28 women with type 1 diabetes and 18 women without diabetes. In contrast, Salonia et al found that testosterone concentrations were higher among women with type 1 diabetes (n = 50) than women without type 1 diabetes (n = 47),³² and Escobar-Morreale et al also noted that testosterone concentrations were higher among women with type 1 diabetes without PCOS (n = 52) compared to controls (n = 18).³³

We conclude that the prevalence of abnormalities in ovarian markers, specifically elevations in AMH, is common in women with type 1 diabetes at an age where they are at increased risk for infertility. Irregular menses are also common although not associated with AMH, and elevations in testosterone are relatively uncommon. In conjunction with previous reports noting decreased fecundity in women with type 1 diabetes, our findings can be used to guide pregnancy planning and fertility management in women with type 1 diabetes in their thirties. Additional investigation of the reasons for decreased fecundity among women with type 1 diabetes should be conducted, particularly regarding abnormal AMH production.

ACKNOWLEDGMENTS

Funding: This work was supported by the National Institutes of Health [U01 DK094176 and U01 DK094157 and DK098129] and through support by the Genetic Clinical Research Centers Program (1993-2007) and Clinical Translational Science Center Program (2006-present), Bethesda, Maryland, USA. Industry contributors have had no role in the DCCT/EDIC study but have provided free or discounted supplies or equipment to support participants' adherence to the study: Abbott Diabetes Care (Alameda, CA), Animas (Westchester, PA), Bayer Diabetes Care (North America Headquarters, Tarrytown, NY), Becton Dickinson (Franklin Lakes, NJ), Eli Lilly (Indianapolis, IN), Extend Nutrition (St. Louis, MO), Insulet Corporation (Bedford, MA), Lifescan (Milpitas, CA), Medtronic Diabetes (Minneapolis, MN), Nipro Home Diagnostics (Ft. Lauderdale, FL), Nova Diabetes Care (Billerica, MA), Omron (Shelton, CT), Perrigo Diabetes Care (Allegan, MI), Roche Diabetes Care (Indianapolis, IN) and Sanofi-Aventis (Bridgewater NJ).

ORCID

C. Kim  <http://orcid.org/0000-0001-9237-0532>

REFERENCES

1. Wiebe J, Santana A, Medina-Rodriguez N, et al. Fertility is reduced in women and in men with type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium (T1DGC). *Diabetologia*. 2014;57:2501-2504.
2. Sjoberg L, Pitkaniemi J, Haapala L, Kaaja R, Tuomilehto J. Fertility in people with childhood-onset type 1 diabetes. *Diabetologia*. 2013;56:78-81.
3. Whitworth K, Baird D, Stene L, Skjaerven R, Longnecker M. Fecundability among women with type 1 and type 2 diabetes in the Norwegian Mother and Child Cohort Study. *Diabetologia*. 2011;54:516-522.
4. Jonasson J, Brismar K, Sparen P, et al. Fertility in women with type 1 diabetes: a population-based cohort study in Sweden. *Diabetes Care*. 2007;30:2271-2276.
5. Codner E, Eyzaguirre F, Iniguez G, et al. Ovulation rate in adolescents with type 1 diabetes mellitus. *Fertil Steril*. 2011;95:197-202.
6. Buschur E, Sarma A, Pietropaolo M, et al. Self-reported autoimmune disease by sex in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care*. 2014;37:E28-E29.
7. Dewailly D, Andersen C, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women. *Hum Reprod*. 2013;20:370-385.
8. Meyer K, Deutscher J, Anil M, Berthold A, Bartsch M, Kiess W. Serum androgen levels in adolescents with type 1 diabetes: relationship to pubertal stage and metabolic control. *J Endocrinol Invest*. 2000;23:362-368.
9. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. 2014;101 3.
10. Purnell J, Hokanson J, Marcovina S, Steffes M, Cleary P, Brunzell J. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the Diabetes Control and Complications Trial. *JAMA*. 1998;280:140-146.
11. Tatone C, Carbone M, Campanella G, et al. Female reproductive dysfunction during ageing: role of methylglyoxal in the formation of advanced glycation endproducts in ovaries of reproductively-aged mice. *J Biol Regul Homeost Agents*. 2010;24:63-72.
12. Nandi A, Poretsky L. Diabetes and the female reproductive system. *Endocrinol Metab Clin North Am*. 2013;42:915-946.
13. Escobar-Morreale H, Roldan-Martin M. Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis. *Diabetes Care*. 2016;39:639-648.
14. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. *Diabetes Care*. 1999;22:99-111.
15. Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. *Diabetes Care*. 1987;10:1-19.
16. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. *N Engl J Med*. 2000;342:381-389.
17. Kim C, Cleary P, Cowie C, et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. *Diabetes Care*. 2014;37:701-708.
18. Kim C, Pan H, Braffett B, et al. AMH in women with and without type 1 diabetes in the EDIC and MBHMS cohorts. *Fertil Steril*. 2016;106:1446-1452.
19. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril*. 2009;91:456.
20. Lebkowska A, Adamska A, Karcewska-Kupcsewska M, et al. Serum anti-Mullerian hormone concentrations in women with polycystic ovary syndrome and type 1 diabetes mellitus. *Metabolism*. 2016;65:804-811.
21. Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism. *J Clin Endocrinol Metab*. 2010;95:4399-4405.
22. Codner E, Iniguez G, Villarroel C, et al. Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. *J Clin Endocrinol Metab*. 2007;92:4742-4746.
23. Codner E, Escobar-Morreale H. Clinical review: hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. *J Clin Endocrinol Metab*. 2007;92:1209-1216.
24. Carmina E, Campagna A, Lobo R. A 20-year follow-up of young women with polycystic ovary syndrome. *Obstet Gynecol*. 2012;119:263-269.
25. Brown Z, Louwers Y, Fong S, et al. The phenotype of polycystic ovary syndrome ameliorates with aging. *Fertil Steril*. 2011;96:1259-1265.
26. Strotmeyer E, Steenkiste A, Foley T Jr, Berga S, Dorman J. Menstrual cycle differences between women with type 1 diabetes and women without diabetes. *Diabetes Care*. 2003;26:1016-1021.
27. Adcock C, Perry L, Lindsell D, Taylor A, Jones J, Dunger D. Menstrual irregularities are more common in adolescents with type 1 diabetes: association with poor glycaemic control and weight gain. *Diabet Med*. 1994;11:465-470.
28. Arrais R, Dib S. The hypothalamus-pituitary-ovary axis and type 1 diabetes mellitus: a mini-review. *Hum Reprod*. 2006;21:327-337.
29. Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. *J Clin Endocrinol Metab*. 2010;95:4542-4548.
30. Soto N, Iniguez G, Lopez P, et al. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. *Hum Reprod*. 2009;24:2838-2844.
31. Soto N, Pruzzo R, Eyzaguirre F, et al. Bone mass and sex steroids in postmenarcheal adolescents and adult women with type 1 diabetes mellitus. *J Diabetes Complications*. 2011;25:19-24.
32. Salonia A, Lanzi R, Scavini M, et al. Sexual function and endocrine profile in fertile women with type 1 diabetes. *Diabetes Care*. 2006;29:312-316.
33. Escobar-Morreale H, Roldan B, Barrio R, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. *J Clin Endocrinol Metab*. 2000;85:4182-4187.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Kim C, Miller RS, Braffett BH, et al. Ovarian markers and irregular menses among women with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications study. *Clin Endocrinol*. 2018;88:453-459. <https://doi.org/10.1111/cen.13546>